NovoSeven

Type: Product
Name: NovoSeven
First reported 4 hours ago - Updated 4 hours ago - 1 reports

The New Anticoagulants: Indications and Risks

Editor's Note: Since October 2010, the US Food and Drug Administration (FDA) has approved 3 new anticoagulants that, for the first time, offer patients with such conditions as stroke in the setting of atrial fibrillation (AF), deep vein thrombosis, and ... [Published Diabetes Care - 4 hours ago]
First reported Jul 14 2014 - Updated Jul 14 2014 - 1 reports

Top 100 Agencies 2014: Biolumina Group

Share this article:Expanding its therapeutic focus helps agency grow its business Biolumina Group has made more headway toward expanding the breadth of therapeutic categories it serves as well as its depth of expertise. Under Ane Jones, president, the ... [Published Medical Marketing And Media - Jul 14 2014]
First reported Jul 14 2014 - Updated Jul 14 2014 - 1 reports

R&D News In Brief: Otezla Disappoints But Dupilumab Doesn’t, Astellas Files Antifungal And NovoSeven Adds Indication

POSTURE study will continue unchanged for Celgene’s PDE-4 inhibitor due to meaningful efficacy seen in a pre-specified subgroup with early-stage disease. Astellas submits an NDA for broad-spectrum antifungal isavuconazole in invasive aspergillosis and ... [Published Health News Daily - Jul 14 2014]
First reported Jul 11 2014 - Updated Jul 12 2014 - 1 reports

Orphan drugs benefit from fast-track approval – but are they getting to patients?

Rare diseases are just that – rare. We may not have heard of them, and we probably don’t know anyone who suffers from them. But rare diseases can have a huge impact on a country’s health care spending as patients can struggle to be treated.Orphan drug ... [Published Pharma Letter - Jul 11 2014]
First reported Jul 09 2014 - Updated Jul 09 2014 - 1 reports

Novo Nordisk A/S : Researchers Submit Patent Application, "Stabilised Solid Compositions of Factor VII Polypeptides", for Approval

By a News Reporter-Staff News Editor at Biotech Week -- From Washington, D.C. , NewsRx journalists report that a patent application by the inventors Jensen, Michael Bech (Alleroed, DK); Hansen, Birthe Lykkegaard (Vaerloese, DK); Kornfelt, Troels (Virum, ... [Published 4 Traders - Jul 09 2014]
First reported Jul 08 2014 - Updated Jul 09 2014 - 2 reports

Novo Nordisk gains FDA backing for new NovoSeven RT indication

Danish diabetes care giant Novo Nordisk’s (NOV: N) hemophilia treatment NovoSeven RT (coagulation factor VIIa [recombinant]) has received approval for an additional indication in the USA.NovoSeven RT has now been cleared by the US Food and Drug Administration ... [Published Pharma Letter - Jul 09 2014]
First reported Jul 07 2014 - Updated Jul 08 2014 - 6 reports

FDA approves Novo Nordisk's drug for rare bleeding disorder

PLAINSBORO, N.J. — Novo Nordisk on Monday announced that the Food and Drug Administration approved the company's NovoSeven RT (coagulation factor VIIa [recombinant]). The drug is the first recombinant treatment for bleeding episodes and perioperative ... [Published Drug Store News - Jul 08 2014]
First reported Jun 15 2014 - Updated Jun 15 2014 - 1 reports

Moats and Growth Drivers Look Solid for Post-Split Baxter

Baxter's strongest competitive advantages have traditionally been on the biopharmaceutical side of its business, thanks to intangible assets including pipeline productivity and a strong global salesforce in hemophilia as well as cost advantages in plasma ... [Published Morningstar.com - Jun 15 2014]
First reported Feb 03 2014 - Updated Feb 03 2014 - 1 reports

Human medicines European public assessment report (EPAR): NovoSeven, eptacog alfa (activated), Revision: 28, Authorised

Entities: NovoSeven
First reported Jan 31 2014 - Updated Jan 31 2014 - 1 reports

Research and Markets: Novoseven RT (Hemophilia A and B) - Forecast and Market Analysis to 2022 Research Report

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/mf7sbv/novoseven_rt) has announced the addition of the "Novoseven RT (Hemophilia A and B) - Forecast and Market Analysis to 2022" report to their offering. The competitive ... [Published Business Wire Professional Services News - Jan 31 2014]

Quotes

"As mentioned, stabilised Factor VII polypeptides are requested so as to minimise the risk of adverse events and to improve safety and efficacy when administering Factor VII polypeptides for therapeutic purposes. Therefore, a still further aspect of the invention relates to the use of Factor VII polypeptide for the preparation of a medicament for treating a Factor VII-responsive syndrome, said medicament comprising a composition comprising; a Factor VII polypeptide and a at least one stability agent selected from the group consisting of a) a combination of an antioxidant and mannitol; b) a combination of methionine and a polyol; c) a combination of a saccharide and mannitol; d) a combination of sucrose and a polyol; and e) methionine, said composition having a moisture content of not more than about 3%."

More Content

All (17) | News (13) | Reports (0) | Blogs (3) | Audio/Video (0) | Fact Sheets (1) | Press Releases (0)
sort by: Date | Relevance
The New Anticoagulants: Indications and Risks [Published Diabetes Care - 4 hours ago]
Top 100 Agencies 2014: Biolumina Group [Published Medical Marketing And Media - Jul 14 2014]
R&D News In Brief: Otezla Disappoints But Dupil... [Published Health News Daily - Jul 14 2014]
Orphan drugs benefit from fast-track approval –... [Published Pharma Letter - Jul 11 2014]
Novo Nordisk A/S : Researchers Submit Patent Ap... [Published 4 Traders - Jul 09 2014]
Novo Nordisk gains FDA backing for new NovoSeve... [Published Pharma Letter - Jul 09 2014]
FDA OKs NovoSeven RT for Glanzmann's Thrombasth... [Published General Medicine eJournal - Jul 08 2014]
FDA approves Novo Nordisk's drug for rare bleed... [Published Drug Store News - Jul 08 2014]
Novo Nordisk Gets FDA Nod for NovoSeven RT [Published Yahoo! Finance - Jul 08 2014]
FDA Approves NovoSeven® RT For The Treatment Of... [Published TheStreet.com - Jul 07 2014]
FDA Approves NovoSeven® RT for the Treatment of... [Published Stock Nod - Jul 07 2014]
FDA Approves NovoSeven® RT for the Treatment of... [Published Ask.com - Jul 07 2014]
FDA Approves NovoSeven® RT for the Treatment of... [Published PR Newswire: Policy & Public Interest - Jul 07 2014]
Moats and Growth Drivers Look Solid for Post-Sp... [Published Morningstar.com - Jun 15 2014]
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - Feb 03 2014]
Research and Markets: Novoseven RT (Hemophilia ... [Published Business Wire Professional Services News - Jan 31 2014]
Fact Sheet for Novo-Nordisk A/S [Published Able2Act - Jul 24 2008]
1
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
FDA Approves NovoSeven® RT for the Treatment of... [Published PR Newswire: Policy & Public Interest - Jul 07 2014]
PLAINSBORO, N.J., July 7, 2014 /PRNewswire/ -- Novo Nordisk today announced the US Food and Drug Administration (FDA) has approved NovoSeven® RT (Coagulation Factor VIIa [Recombinant]) as the first recombinant treatment for bleeding episodes and perioperative ...
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - Feb 03 2014]
Research and Markets: Novoseven RT (Hemophilia ... [Published Business Wire Professional Services News - Jan 31 2014]
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/mf7sbv/novoseven_rt) has announced the addition of the "Novoseven RT (Hemophilia A and B) - Forecast and Market Analysis to 2022" report to their offering. The competitive ...
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.